Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

3.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst
Via Benzinga
Revance Therapeutics: Q2 Earnings Insights
  Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics: Earnings Outlook
  Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Recap: Revance Therapeutics Q1 Earnings
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Revance Therapeutics Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options 
Via NewMediaWire
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. 
Via Benzinga
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by... 
Via SBWire
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for... 
Via Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
From Revance Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. 
Via Benzinga
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics: Q4 Earnings Insights
Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Deadline Today Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.